Pharma — April 2023
-
FDA staff flag concerns over broad use of Lynparza combo in prostate cancer FDA staff flag concerns over broad use of Lynparza combo in prostate cancer
-
Orbital bags $270 million to advance RNA-based therapeutics https://firstwordpharma.com/story/5732256?nle=113791&aid=5732256&nlc=30
-
Novartis tees up filings for iptacopan in PNH after detailing second study win https://firstwordpharma.com/story/5732247?nle=113791&aid=5732247&nlc=30
-
GSK backs full-year view as Q1 sales slip, but top forecasts
https://firstwordpharma.com/story/5732233?nle=113791&aid=5732233&nlc=30 -
Vabysmo leads growth in Roche's pharma unit during Q1 https://firstwordpharma.com/story/5732193?aid=5732193
-
Eli Lilly stiger efter opjustering trods svagere end ventet indtjening https://www.proinvestor.com/investornyt/974781/eli-lilly-stiger-efter-opjustering-trods-svagere-end-ventet-indtjening
-
Kort video - Pharma og biotek-opdatering UGE 17: Demant ' GN Store Nord ' Novo Nordisk ' Genmab ' Zealand Pharma ' Hansa Biopharma https://www.proinvestor.com/boards/112327
-
Is This Big Pharma Stock a Buy for Dividend Investors? https://www.proinvestor.com/investornyt/974944/is-this-big-pharma-stock-a-buy-for-dividend-investors
-
Lundbeck og partner får FDA-godkendelse til skizofrenimiddel https://www.proinvestor.com/investornyt/975561/lundbeck-og-partner-far-fda-godkendelse-til-skizofrenimiddel
-
JP Morgan Maintains Eli Lilly And (LLY) Overweight Recommendation https://www.proinvestor.com/investornyt/976278/jp-morgan-maintains-eli-lilly-and-lly-overweight-recommendation
-
Credit Suisse Maintains Ascendis Pharma A (ASND) Neutral Recommendation https://www.proinvestor.com/investornyt/976412/credit-suisse-maintains-ascendis-pharma-a-asnd-neutral-recommendation
-
Morgan Stanley Maintains Ascendis Pharma A (ASND) Equal-Weight Recommendation https://www.proinvestor.com/investornyt/976413/morgan-stanley-maintains-ascendis-pharma-a-asnd-equal-weight-recommendation
-
Cantor Fitzgerald Maintains Ascendis Pharma A (ASND) Overweight Recommendation https://www.proinvestor.com/investornyt/976414/cantor-fitzgerald-maintains-ascendis-pharma-a-asnd-overweight-recommendation
-
HC Wainwright & Co. Maintains ASLAN Pharmaceuticals Ltd - ADR (ASLN) Buy Recommendation https://www.proinvestor.com/investornyt/976415/hc-wainwright-amp-co-maintains-aslan-pharmaceuticals-ltd-adr-asln-buy-recommendation
-
1 No-Brainer Pharma Stock to Buy With $1,000 Right Now
https://www.proinvestor.com/investornyt/976450/1-no-brainer-pharma-stock-to-buy-with-1000-right-now -
Will Pfizer Stock See Higher Levels Post Q1 Earnings? https://www.proinvestor.com/investornyt/976496/will-pfizer-stock-see-higher-levels-post-q1-earnings
-
AbbVie's Blockbuster Is Falling Fast. Time to Sell? https://www.proinvestor.com/investornyt/976509/abbvies-blockbuster-is-falling-fast-time-to-sell
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind